Clinical Trial Update: The DART Study- Daratumumab Treatment in ITP [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating daratumumab for immune thrombocytopenia (ITP) is ongoing with status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Ostfold Hospital Trust | Conditions: ITP | Phase 2 | Status: UNKNOWN